Login to Your Account



Financings Roundup

Latest IPO Filing Sees HCV Player Enanta Seeking $69M

By Catherine Shaffer
Staff Writer

Wednesday, November 7, 2012
financings_resized.jpg

Enanta Pharmaceuticals Inc., of Watertown, Mass., filed with the SEC an S-1 for an initial public offering (IPO) worth $69 million to support its work in the area of hepatitis C virus (HCV).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription